scholarly journals Reversible Thrombocytopenia after Gabapentin in an HIV-Positive Patient

2018 ◽  
Vol 2018 ◽  
pp. 1-2
Author(s):  
Mohammed Basith ◽  
Andrew Francis ◽  
Alfredo Bellon
Keyword(s):  
At Risk ◽  
Human Immunodeficiency Virus ◽  
Psychiatric Care ◽  
Hiv Positive ◽  
Inpatient Psychiatric Care ◽  
Immunodeficiency Virus ◽  
The Us ◽  
Patients At Risk ◽  
History Of ◽  
Severe Anxiety

Gabapentin has become increasingly used in psychiatric practice specifically for anxiety disorders. Even though gabapentin is not approved by the US Food and Drug Administration to treat anxiety, physicians sometimes use it as an alternative to benzodiazepines in patients with a history of substance abuse. Gabapentin is also prescribed when individuals are at risk of thrombocytopenia which is not considered a side effect. Among patients at risk of thrombocytopenia are those positive for human immunodeficiency virus (HIV). Here we present a case of an HIV-positive man who presented for inpatient psychiatric care with severe anxiety and a history of alcohol and benzodiazepine abuse. In this patient, gabapentin worsened thrombocytopenia after repeated exposure to this medication. We suggest caution when considering gabapentin for patients with preexisting low platelet counts, as there seems to be a risk for worsening thrombocytopenia with this antiepileptic in the presence of HIV infection.

Pneumocystis carinii infection in bilateral aural polyps in a human immunodeficiency virus-positive patient

2002 ◽  
Vol 116 (4) ◽  
pp. 288-290 ◽  
Author(s):  
C. V. Praveen ◽  
R. M. Terry ◽  
M. Elmahallawy ◽  
C. Horsfield
Keyword(s):  
Human Immunodeficiency Virus ◽  
Opportunistic Infection ◽  
Pneumocystis Carinii ◽  
Lymphatic Vessels ◽  
Blood Stream ◽  
Positive Patient ◽  
Hiv Positive ◽  
Immunodeficiency Virus ◽  
History Of ◽  
Pneumocystis Carinii Infection

Pneumocystis carinii is an opportunistic infection found in patients with impaired immunity. Under favourable conditions the parasite can spread via the blood stream or lymphatic vessels and cause extrapulmonary dissemination. We report a case of P carinii infection presenting as bilateral aural polyps, otitis media and mastoiditis in human immunodeficiency (HIV)-positive patient with no history of prior or concomitant P carinii infection.

scholarly journals Human immunodeficiency virus and tuberculosis co-infection in Saudi Arabia

2002 ◽  
Vol 08 (06) ◽  
pp. 749-753
Author(s):  
A. A. Alrajhi ◽  
A. Nematallah ◽  
S. Abdulwahab ◽  
Z. Bukhary
Keyword(s):  
Human Immunodeficiency Virus ◽  
Saudi Arabia ◽  
Hiv Positive ◽  
First Line ◽  
Patient History ◽  
Hiv Seroprevalence ◽  
Tuberculosis Patients ◽  
Treatment Type ◽  
Immunodeficiency Virus ◽  
History Of

Our study determined the rate of screening tuberculosis patients for HIV co-infection and the HIV seroprevalence among them. We retrospectively reviewed medical charts of 437 patients diagnosed with tuberculosis from 1995-2000 in Riyadh, Saudi Arabia. Screening was done for 178 [41%] patients: 2 [1.1%] of these were found to be HIV positive. Prior to screening, 4 patients were already known to be HIV positive. Males were screened more often than females [45% and 36% respectively]. All HIV positive patients were males. Screening was not affected by origin of the patient, history of prior tuberculosis or treatment, type of tuberculosis involvement or resistance to first line anti-tuberculosis agents. In Saudi Arabia, screening for HIV in tuberculosis patients remains underutilized. Among screened patients, seropositivity was low.

scholarly journals Disparities in CD4+ T-Lymphocyte Monitoring Among Human Immunodeficiency Virus-Positive Medicaid Beneficiaries: Evidence of Differential Treatment at the Point of Care

2014 ◽  
Vol 1 (2) ◽  
Author(s):  
Anna C. Davis ◽  
Greg Watson ◽  
Nadereh Pourat ◽  
Gerald F. Kominski ◽  
Dylan H. Roby
Keyword(s):  
Human Immunodeficiency Virus ◽  
Cell Count ◽  
T Lymphocyte ◽  
Hiv Positive ◽  
Fee For Service ◽  
Cd4 Cell Count ◽  
Immunodeficiency Virus ◽  
History Of ◽  
Medicaid Beneficiaries ◽  
Cd4 Cell

Abstract Background.  Monitoring of immune function, measured by CD4+ T-lymphocyte (CD4) cell count, is an essential service for people with human immunodeficiency virus (HIV). Prescription of antiretroviral (ARV) medications is contingent on CD4 cell count; patients without regular CD4 monitoring are unlikely to receive ARVs when indicated. This study assesses disparities in CD4 monitoring among HIV-positive Medicaid beneficiaries. Methods.  In this retrospective observational study, we examined 24 months of administrative data on 2250 HIV-positive, continuously enrolled, fee-for-service, Medicaid beneficiaries with at least 2 outpatient healthcare encounters. We used logistic regression to evaluate the association of patient demographics (age, gender, race or ethnicity, and language) with receipt of at least 1 CD4 test per year, controlling for other potentially confounding variables. Results.  Having a history of ARV therapy was positively associated with receipt of CD4 tests. We found racial or ethnic, gender, and age disparities in CD4 testing. Among individuals with a history of ARV use, all racial or ethnic groups were significantly less likely to have CD4 tests than White non-Latinos (African Americans, odds ratio [OR] = 0.35, P < .0001; Asian or Pacific Islanders, OR = 0.31, P = .0047; and Latinos, OR = 0.42, P < .0001). Conclusions.  We identified disparities in receipt of CD4 tests, a finding that may elucidate one potential pathway for previously reported disparities in ARV treatment. Further qualitative and quantitative research is needed to identify the specific factors that account for these disparities, so that appropriate interventions can be implemented.

Human Immunodeficiency Virus-Infected Adolescents: The First 50 Patients in a New York City Program

PEDIATRICS ◽  
1993 ◽  
Vol 91 (4) ◽  
pp. 730-735 ◽  
Author(s):  
Donna Futterman ◽  
Karen Hein ◽  
Nancy Reuben ◽  
Ralph Dell ◽  
Nathan Shaffer
Keyword(s):  
New York ◽  
Human Immunodeficiency Virus ◽  
New York City ◽  
High Risk ◽  
York City ◽  
Hiv Positive ◽  
Survival Sex ◽  
Immunodeficiency Virus ◽  
History Of ◽  
Hiv Negative

To address the unique manifestations of human immunodeficiency virus (HIV) among adolescents aged 13 through 21 years, a comprehensive evaluation and treatment program for high-risk and HIV-positive adolescents was developed in New York City in 1987. Among HIV-infected youth, mean age of testing was 18.2 years. One third of the HIV-positive patients were female and four fifths were African-American or Hispanic. No significant differences were found between HIV-positive (n = 50) and HIV-negative (n = 43) patients for age at first intercourse, injecting or other illicit drug use, history of sexually transmitted diseases, or survival sex (exchange of sex for money or drugs). HIV-positive males were more likely than HIV-negative males to have engaged in anal intercourse and to report a history of sexual abuse. Among infected females, 82% acquired HIV through heterosexual intercourse. Almost half (48%) of HIV-positive adolescents had significant immune dysfunction at the time of their initial visit (CD4 <500/mm3) and were eligible for zidovudine. Many HIV-positive adolescents continued high-risk behaviors such as intercourse without condoms, particularly those with ongoing dependence on drugs or alcohol. With the epidemic of HIV infection increasing nationwide among adolescents, specialized, comprehensive programs are needed to counsel and treat HIV-infected adolescents and youth in high-risk situations.

Sign in / Sign up

Export Citation Format

Share Document